期刊文献+

姜黄素对小鼠帕金森病模型行为学的影响 被引量:2

下载PDF
导出
摘要 目的探讨姜黄素对C57BL/6小鼠帕金森病模型行为学的影响及常用行为学测试的比较。方法取30只C57BL/6雄性小鼠随机分成3组:MPTP模型组、姜黄素治疗组和正常对照组;模型组、姜黄素组采用1-甲基.4.苯基1,2,3,6-四氢吡啶(MPTP)腹腔注射造模,正常对照组给予等量0.9%氯化钠注射液腹腔注射。姜黄素组予姜黄素腹腔注射,连续1周。各组小鼠在最后1~P.MPTP或0.9%氯化钠注射液注射后7d予行为学指标检测。结果姜黄素能改善帕金森病模型小鼠行为学中旷场试验、悬挂试验等相关指标(P〈0.05)。对爬杆试验相关指标无明显改善作用。结论姜黄素可改善帕金森病模型小鼠行为学变化。爬杆试验、悬挂试验较易受主观因素影响,旷场试验是更为客观的检测方法。 Objective To observe the curative effect of Curcumin on C57BL/6 mice behavioral manifestation in PD models, and to compare three behavioral tests which are often used in PD models. Methods 30 C57BL/6 mice were randomly divided into three groups as control group, MPTP+Curcumin group and model group. Mice in MPTP+Curcumin group and model group received intraperitoneal injection with MPTP to establish PD models, and mice in control group received intraperitoneal injection with the same amount of saline solution for 1 week. Mice in MPTP+Curcumin group received intraperitoneal injection with Curcumin the same time. Animal behavior detections were carried out on the 7th day after injection. Results Curcumin could improve the general condition and behavioral manifestation in open field test and traction test ( P〈0.05 ) , while the effect on pole test was not significant. Conclusions This study for behaviors of mice in the three groups further confirmed that Curcumin could treat PD model mice behavior to some degree. Subjective factor was inclined to be involved in pole test and traction test. Open field test is a more objective ethological method for MPTP model mice of Parkinson's disease.
出处 《浙江临床医学》 2016年第3期400-401,404,共3页 Zhejiang Clinical Medical Journal
基金 浙江省中医药青年人才基金项目(No.2015zQ017)
关键词 1-甲基-4-苯基1 2 3 6-四氢吡啶(MPTP) 帕金森病 姜黄素 行为学测试 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine ( MPTP ) Parkinson' s disease Curcumin Behavioral test
  • 相关文献

参考文献19

  • 1Chen W, Xu ZM, Wang G, et al. Non-motor symptoms of Parkmson's disease in China: a review of the literature. Parkinsonism Relat Disord,2012,18(5) :446-452.
  • 2Tolleson CM, Fang JY. Advances in the mechanisms of Parkinson's disease. Discov Med,2013,15(80):61-66.
  • 3Horny kiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol,1987, 45:19-34.
  • 4Schulz -Schaeffer WJ. The synaptic pathology of alpha- synuclein aggregation in dementia with Lewy bodies, Parkinson' s disease and Parkinsons disease dementia. Acta Neuropathol,2010,120(2) : 131-143.
  • 5Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord,2013,28(1):31-40.
  • 6Boassa D,Berlanga ML,Yang MA, et al. Mapping the subceUular distribution of t -synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis. J Neurosci,2013, 33(6):2605-2615.
  • 7Bharat B Aqqarwal, Kuzhuvelil B Harikumar. Potential therapeutic effect of curucmin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, meta-bolic, autoimmune and neoplastic diseases. IntJ Bio-chem Cell Biol,2009, 41(1): 40-59.
  • 8Huang Han-chang, Xu Ke, Jiang Zhao-feng. Curcumin-mediated neuroprotection against amyloid- β-induced mitochondrial dysfunction involves the inhibition of GSK-3 β. J Alzheimers Dis,2012,32(4):981-996.
  • 9Mansouri Zahra, Sabetkasaei Masoumeh, Moradi Fatemeh, et al. Curcumin has neuroprotection effect on homocysteine rat model of Parkinson. J Mol Neurosci, 2012,47 (2) :234-242.
  • 10Gulrana Khuwaja,Mohd Moshahid Khan,Tauheed Ishrat, et al. Neuroprotective effects of curcumin on 6-hydroxydopamine- induced Parkinsonism in rats: behavioral,neurochemical and immunohistochemical studies. Brain Research, 2011,1368(12):254-263.

二级参考文献16

  • 1李俊,汤晓林,徐叔云.高效液相电化学检测器检测大鼠中枢单胺递质[J].安徽医科大学学报,1996,31(4):264-266. 被引量:10
  • 2Heikkila RE, Sonsalla PK. The MPTP-- treated mouse as a model of parkinsonism: how good is it?[J]. Neurochem Int, 1992, 20 Suppl: 299--303.
  • 3Jakowec MW, Petzinger GM. 1 -- methyl-- 4 -- phenyl-- 1,2,3,6 --tetrahydropyridine--lesi--oned model of parkinson's disease, with emphasis on mice and nonhuman primates[J]. Comp Med, 2004,54(5) :497--513.
  • 4Ogawa N, Hirose Y,Ohara S,et al. A simple quantitative bradykinesia test in MPTP--treated mice[J]. Res Commun Chem Pathol Pharmacol, 1985,50(3) :435--441.
  • 5Petroske E, Meredith GE,Callen S, et al. Mouse model of Parkinsonism:a comparison between subacute MPTP and chronic MPTP/probenecid treatment [J ]. Neuroscience, 2001,106 ( 3 ) : 589-- 601.
  • 6Arai N, Misugi K, Goshima Y, et al. Evaluation of a 1- methyl -- 4 -- phenyl -- 1,2,3,6-- tetrahydropyridine(MPTP) -- treated C57 black mouse model for parkinsonism[J]. Brain Res, 1990, 515(1--2) :57--63.
  • 7Sedelis M, Hofele K, Auburger GW. MPTP susceptibility in the raouse: behavior, neurochemical and histological analysis of gender and strain differences[J]. Behav Genet,2000,30(3) :171--182.
  • 8Chiueh C C,Miyake H,Peng M T.Role of dopamine autoxidalion,hydroxyl radical generation,and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism[J].Adv Neurol,1993,60:251-258.
  • 9Heikkila R E,Manzino L,Cabbat F S,et al.Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrrostriatal pathway in mice[J].Neurosci Lett,1985,58(1):133 - 137.
  • 10Langston J W,Irwin I.MPTP:current concepts,and controversies[J].Clin Neropharmaeol,1986,9:485 -507.

共引文献22

同被引文献22

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部